Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia

No abstract is available for this paper.

• Publication year

  1999

• Venue

  British Journal of Haematology

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.1999.01598.xPMID 10468856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.

  1998cited by this paper
• Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis.

  1998cited by this paper
• Evidence for integrin receptor involvement in megakaryocyte‐fibroblast interaction: A possible pathomechanism for the evolution of myelofibrosis

  1998cited by this paper
• The role of transforming growth factor‐β in PEG‐rHuMGDF‐induced reversible myelofibrosis in rats

  1997cited by this paper
• The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats.

  1997cited by this paper
• Idiopathic myelofibrosis: pathogenesis, natural history and management.

  1997cited by this paper
• The effects of anagrelide on human megakaryocytopoiesis

  1997cited by this paper
• Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia

  1997cited by this paper
• Anagrelide as a New Platelet-Lowering Agent in Essential Thrombocythemia: Mechanism of Action, Efficacy, Toxicity, Current Indications

  1997cited by this paper
• Immunohistochemical study of Ulex europaeus agglutinin 1 (UEA-1) binding of megakaryocytes in bone marrow biopsy specimens: demonstration of heterogeneity in staining pattern reflecting the stages of differentiation.

  1996cited by this paper
• A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.

  1996cited by this paper
• Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice.

  1996cited by this paper
• Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

  1996cited by this paper
• Immunohistochemical study of Ulex europaeus agglutinin 1 (UEA-1) binding of megakaryocytes in bone marrow biopsy specimens: demonstration of heterogeneity in staining pattern reflecting the stages of differentiation.

  1996cited by this paper
• Agnogenic myeloid metaplasia.

  1995cited by this paper
• Platelet-derived growth factor (PDGF)-AA, -AB, and -BB induce differential chemotaxis of early-passage rat lung fibroblasts in vitro.

  1995cited by this paper
• Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice.

  1995cited by this paper
• TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.

  1995cited by this paper
• Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.

  1992cited by this paper
• Increased intraplatelet levels of platelet‐derived growth factor and transforming growth factor‐β in patients with myelofibrosis with myeloid metaplasia

  1991cited by this paper
• Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes.

  1990cited by this paper
• A major part of platelet-derived growth factor purified from human platelets is a heterodimer of one A and one B chain.

  1988influential reference
• Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor‐β on the growth of human marrow fibroblasts

  1988cited by this paper
• Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells

  1987influential reference
• Inhibition of Platelet Production Induced by an Antiplatelet Drug, Anagrelide, in Normal Volunteers

  1984cited by this paper
• Agnogenic myeloid metaplasia.

  1974influential reference

• Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms

  2021cites this paper
• Aspirin responsive platelet thrombophilia in essential thrombocythemia and polycythemia vera

  2013cites this paper
• Bone marrow fibrosis reversal after use of hydroxyurea in a patient with myelofibrosis

  2013cites this paper
• Anagrelide hydrochloride for essential thrombocythemia

  2013cites this paper
• Anagrelide

  2012cites this paper
• MYELOPROLIFERATIVE AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS AND RELATED CONDITIONS

  2009cites this paper
• Anagrelide: 20 years later

  2009cites this paper
• Guidelines for the diagnosis and treatment of patients with polycythemia vera, essential thrombocythemia and primary myelofibrosis.

  2009cites this paper
• Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of Transplantation

  2008cites this paper
• A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

  2007cites this paper
• Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment

  2007cites this paper
• Myelofibrosis: biology and treatment options

  2007cites this paper
• Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis

  2006cites this paper
• Effects of Anagrelide on Megakaryopoiesis and Platelet Production

  2006cites this paper
• Neues Therapiekonzept bei Thrombozythämie: Anagrelid

  2006cites this paper
• Effects of anagrelide on megakaryopoiesis and platelet production.

  2006cites this paper
• Thalidomide therapy for myelofibrosis with myeloid metaplasia

  2006cites this paper
• The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera

  2006influential citation
• Advances in the therapy of chronic idiopathic myelofibrosis.

  2006cites this paper
• Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

  2006cites this paper
• Juvenile rheumatoid arthritis with myelofibrosis with myeloid metaplasia

  2005cites this paper
• Conventional and new treatment options for myelofibrosis with myeloid metaplasia.

  2005cites this paper
• New approaches in the treatment of myelofibrosis

  2005cites this paper
• Anagrelide for control of thrombocytosis due to myeloproliferative disorders.

  2005cites this paper
• Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.

  2005cites this paper
• The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

  2005cites this paper
• Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia

  2005cites this paper
• The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

  2005cites this paper
• Pathogenesis of myelofibrosis with myeloid metaplasia.

  2005cites this paper
• A critical review of anagrelide therapy in essential thrombocythemia and related disorders

  2005cites this paper
• Modern management of myelofibrosis

  2005cites this paper
• Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients

  2005cites this paper
• Molecular and Preclinical Aspects of Anagrelide Action

  2004cites this paper
• Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.

  2004cites this paper
• Chronic myelogenous leukemia and myeloproliferative disease.

  2004cites this paper
• Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia

  2004cites this paper
• Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.

  2004cites this paper
• Anagrelide: an update on its mechanisms of action and therapeutic potential

  2004cites this paper
• Doctor's Brochure 2004 Myeloproliferative Disorders: MPDs Essential Thrombocythemia: ET Polycythemia Vera: PV Chronic Idiopathic Myelofibrosis: IMF

  2004cites this paper
• Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.

  2003cites this paper
• Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?

  2003cites this paper
• Chronic lymphoid disorder Acute lymphoid leukemia Chronic myeloid disorder Acute myeloid leukemia Myeloid disorders Lymphoid disorders Hematologic malignancies

  2003cites this paper
• The forgotten myeloproliferative disorder: myeloid metaplasia.

  2003cites this paper
• Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.

  2003cites this paper
• Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review

  2002cites this paper
• Thalidomide treatment in myelofibrosis with myeloid metaplasia

  2002cites this paper
• Bone Marrow Angiogenesis in Systemic Mast Cell Disease

  2002cites this paper
• [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].

  2002cites this paper
• Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.

  2002cites this paper
• Other secondary sequelae of treatments for myeloproliferative disorders.

  2002cites this paper
• Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.

  2001cites this paper
• Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.

  2001cites this paper
• Myelodysplasia with fibrosis: a distinct entity?

  2001cites this paper
• Myelofibrosis with myeloid metaplasia.

  2000cites this paper
• Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline- containing regimens

  1997cites this paper